Split History
ETFs Holding APHB »    APHB Historical Stock Prices »
Video: What is a Stock Split?


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
AmpliPhi Biosciences is a biotechnology company focused on the discovery, development and commercialization of phage therapeutics. Phage therapeutics use bacteriophages, a family of viruses, to kill pathogenic bacteria. Co. is developing phage products to combat multi- or pan-drug-resistant bacterial pathogens. Co. primary product candidate is AB-SA01, for the treatment of Staphylococcus aureus (S. aureus) infections, including methicillin-resistant S. aureus. Co. also has another product candidate in earlier stage development, AB-PA01 for the treatment of P. aeruginosa infections, and an additional discovery program, AB-CD01 for the treatment of C. difficile infections. According to our APHB split history records, AmpliPhi Biosciences has had 1 split.
APHB split history picture
AmpliPhi Biosciences (APHB) has 1 split in our APHB split history database. The split for APHB took place on April 25, 2017. This was a 1 for 10 reverse split, meaning for each 10 shares of APHB owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 100 share position following the split.

When a company such as AmpliPhi Biosciences conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share. Looking at the APHB split history from start to finish, an original position size of 1000 shares would have turned into 100 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into AmpliPhi Biosciences shares, starting with a $10,000 purchase of APHB, presented on a split-history-adjusted basis factoring in the complete APHB split history. APHB split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 12/17/2007
End date: 12/15/2017
Start price/share: $16.80
End price/share: $0.96
Dividends collected/share: $0.00
Total return: -94.29%
Average Annual Total Return: -24.88%
Starting investment: $10,000.00
Ending investment: $571.76
Years: 10.00
Date Ratio
04/25/20171 for 10
APHB is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

APPY Split History
APRI Split History
ARA Split History
ARCT Split History
ARNA Split History
ARTC Split History
ARWR Split History
ASMB Split History
ASTM Split History
ATE Split History

Neogen Corporation (NEOG)
The Manitowoc Company, Inc. (MTW)
Amedica Corporation (AMDA)
Patrick Industries, Inc. (PATK)
Whiting Petroleum Corporation (WLL)
SPI Energy Co., Ltd. (SPI)
CytRx Corporation (CYTR)
Marathon Patent Group, Inc. (MARA)
WisdomTree U.S. Total Earnings Fund (EXT)
WisdomTree U.S. Earnings 500 Fund (EPS)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

APHB Insider Buying

APHB Split History | www.SplitHistory.com | Copyright © 2013 - 2017, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.